The Centers for Disease Control and Prevention (CDC) has set aside $1.6 million to help fund a previously suspended, controversial hepatitis b vaccine trial in Guinea-Bissau, West Africa. The decision has reignited intense debate and criticism from public health officials and infectious disease experts regarding the ethics of the study, which would withhold the standard birth dose of the vaccine from newborns.
Details of the Guinea-Bissau Vaccine Study
The randomized controlled trial, spearheaded by Danish researchers including Christine Stabell Benn and led through the Bandim Health Project, intends to enroll approximately 14,000 newborns in the impoverished West African nation. Under the study design, half of the participating infants would receive the hepatitis B vaccine at birth, while the other half would have their vaccination delayed until two months of age. The research aims to investigate whether a birth dose of the vaccine has potential negative side effects, such as skin ailments or neurodevelopmental disorders.
Critics, however, point out that the hepatitis B birth dose has been proven safe and effective over decades of global use and is recommended internationally to prevent chronic infection. Australian infectious disease specialist Benjamin Cowie warned that withholding the vaccine in a high-prevalence setting like Guinea-Bissau could leave vulnerable infants at risk of chronic hepatitis B, liver cancer, and liver failure.
CDC Funding Allocation and Expiring Grants
According to reports, staff within the CDC director’s office instructed the agency’s budget office in late September to earmark $1.6 million for the study. The funding is reportedly being pulled from money originally directed by Congress for CDC global health security programs—funds that might otherwise support efforts such as combating active outbreaks like Ebola. An additional matching sum of private funding is set to be provided by the Pershing Square Foundation.
Sources familiar with the matter indicated that the decision to push the grant forward was heavily driven by the imminent expiration of the funds within the CDC budget. Furthermore, researchers face an inexorable timeline: beginning in 2028, Guinea-Bissau is scheduled to officially implement the birth dose of the hepatitis B vaccine for all newborns as part of its national policy, which would eliminate the premise that not providing the birth dose aligns with the country’s current standard of care.
Researcher Defense and Next Steps
Lead Danish researcher Christine Stabell Benn has defended the clinical trial, stating that the project complies with current national policies in Guinea-Bissau and has received review and approval from the competent national ethics committee. Study leaders maintain that participating children will not receive less than the standard of care currently available in the region and will not be denied treatment they would otherwise obtain.
Despite the allocation of funds by CDC staff, the suspended trial cannot officially begin until all necessary national authorizations and final approvals are formally secured in Guinea-Bissau, leaving the future of the controversial study under close international scrutiny.
